# 2026-13145: Company Applies to Import Psilocybin and Oxycodone Legally

2026-13145, Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI), is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-06-30, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 30, 2026. Such persons may also file a written request for a hearing on the application on or before July 30, 2026.; PRIA reads it as touching household money (as of 2026-07-07).

- Canonical: https://policyrisk.com/federal-register/2026-13145
- As of: 2026-07-07
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13145
- Title: Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 39635
- Published: 2026-06-30
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 30, 2026. Such persons may also file a written request for a hearing on the application on or before July 30, 2026.
- Comments close: 2026-07-30
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-07

## In one line

Company Applies to Import Psilocybin and Oxycodone Legally

## Summary

Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.

## Abstract

Almac Clinical Services Incorp. (ACSI) has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

## Effects PRIA read

- Application to Import Trial Drugs: benefit, low. Almac Clinical Services Incorp. applied on May 5, 2026 to be registered to import psilocybin (Schedule I) and five Schedule II drugs — oxycodone, hydromorphone, morphine, tapentadol, and fentanyl — as finished dosage form units for clinical trial purposes only. Registered bulk manufacturers and oth…
- Importation Limited; No Commercial Sale: cost, medium. The registration, if granted, would authorize only the import of the listed drugs as finished dosage form units for clinical trial purposes and explicitly states that no other activities for these drug codes are authorized. Authorization will not extend to importation of FDA-approved or non-approve…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-13145 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/30/2026-13145/importer-of-controlled-substances-application-almac-clinical-services-incorp-acsi)
- [2026-13145 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-30/pdf/2026-13145.pdf)

## Related
- [Previous: 2026-13144, Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC](https://policyrisk.com/federal-register/2026-13144)
- [Next: 2026-13146, Privacy Act of 1974; System of Records](https://policyrisk.com/federal-register/2026-13146)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13145 (as of 2026-07-07).
